scout
Commentary|Videos|December 7, 2025

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

Fact checked by: Ashling Wahner , Chris Ryan

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

“We had a cohort of 21 patients, one-third of which [had] KMT2A rearrangements. [In this population], the overall response rate was high, [at 86%]. The complete response [CR]/CR with partial hematologic recovery rate was also [86%].”

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from the phase 2 SAVE trial (NCT05360160) evaluating revumenib (Revuforj) plus decitabine, cedazuridine, and venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME